TransMedics Group Stock (NASDAQ:TMDX)
Previous Close
$82.92
52W Range
$67.77 - $177.37
50D Avg
$124.47
200D Avg
$122.35
Market Cap
$2.59B
Avg Vol (3M)
$1.49M
Beta
2.07
Div Yield
-
TMDX Company Profile
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX Performance
Peer Comparison
Ticker | Company |
---|---|
MASI | Masimo Corporation |
OFIX | Orthofix Medical Inc. |
DCTH | Delcath Systems, Inc. |
LUNG | Pulmonx Corporation |
INMD | InMode Ltd. |
PODD | Insulet Corporation |
NPCE | NeuroPace, Inc. |
TELA | TELA Bio, Inc. |
PEN | Penumbra, Inc. |
NARI | Inari Medical, Inc. |
INSP | Inspire Medical Systems, Inc. |
SWAV | ShockWave Medical, Inc. |
CVRX | CVRx, Inc. |
SILK | Silk Road Medical, Inc |